Jessica Serra | Head, IR and ESG |
Mark Foley | President and CEO |
Toby Schilke | CFO |
Dr. Abhay Joshi | COO and President, R&D and Product Operations |
Dustin Sjuts | Chief Commercial Officer, Aesthetics and Therapeutics |
Aubrey Rankin | President, Innovation and Technology |
Seamus Fernandez | Guggenheim |
Terence Flynn | Goldman Sachs |
Annabel Samimy | Stifel |
David Amsellem | Piper Sandler |
Tim Lugo | William Blair |
Balaji Prasad | Barclays |
Serge Belanger | Needham & Company |
Ken Cacciatore | Cowen |
Vamil Divan | Mizuho |
Chris Bialas | H. C. Wainright |
Good day, everyone. Welcome to Revance Therapeutics Second Quarter 2021 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 5, 2021. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance please go ahead, ma’am.
Joining us on the call today from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Tobin Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr.